@article{JGO14507,
author = {Irene Giacomelli and Daniele Scartoni and Homan Mohammadi and William F. Regine and Michael D. Chuong},
title = {Does lymphocyte-to-monocyte ratio before, during, or after definitive chemoradiation for locally advanced pancreatic cancer predict for clinical outcomes?},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {4},
year = {2017},
keywords = {},
abstract = {Background: Elevated pre-treatment lymphocyte (L) to monocyte (M) ratio (LMR) in peripheral blood has been suggested to correlate with improved survival in some malignancies, but data in the context of pancreatic cancer (PC) is limited. The aim of this study was to evaluate the prognostic significance of LMR before, during and after definitive chemoradiotherapy (CRT) for locally advanced pancreatic cancer (LAPC).
Methods: We retrospectively reviewed 57 patients with LAPC treated with definitive CRT at a single institution from 2005 to 2013. Complete blood counts were obtained before (TP1), during the third week (TP2) and at the end of CRT (TP3). Univariate analysis (UVA) included gender, age, body mass index, pretreatment CA19-9, T stage, N stage, induction chemotherapy (ICT), absolute L count (TP1, TP2, TP3), absolute M count (TP1, TP2, TP3), LMR (TP1, TP2, TP3), and relative LMR changes (TP2 ÷ TP1, TP3 ÷ TP1, TP3 ÷ TP2).
Results: Median follow-up was 14 months. Twelve patients received ICT. Median LMR was 2.7 (range, 0.8–5.25), 1.4 (range, 0.3–5) and 0.98 (range, 0.3–3.4) at TP1, TP2 and TP3, respectively. Superior PFS was significantly associated with an absolute M count during CRT 0.32 (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/14507}
}